Management of LDL-C Levels in Patients with Clinical ASCVD

Introduction to LDL-C Management

The American College of Cardiology recommends maintaining the current maximally tolerated statin therapy and adding ezetimibe to achieve the LDL-C goal of <70 mg/dL, rather than increasing the statin dose 1, 2

There is no RCT evidence supporting titration to specific LDL-C numerical goals, such as proving that achieving <70 mg/dL improves outcomes over <80 mg/dL through dose escalation, according to the American College of Cardiology 3
The 2013 ACC/AHA guideline explicitly states that no direct data from RCTs confirm the efficacy of using LDL-C goals to guide therapy through dose titration, as stated by the American College of Cardiology 3
Current guidelines recommend fixed-dose intensity strategies, such as high-intensity, moderate-intensity, or low-intensity statin therapy, rather than titrating to arbitrary numerical targets, as recommended by the American Heart Association and the American College of Cardiology 1, 3

If LDL-C is ≥70 mg/dL on maximally tolerated statin therapy, it is reasonable to add ezetimibe, with a Class IIa recommendation and Level B-R evidence, according to the American College of Cardiology 1
The American College of Cardiology recommends considering non-statin therapies in very high-risk patients with LDL-C ≥55 mg/dL, as individuals achieving LDL-C <55 mg/dL experience lower event rates 4
Ezetimibe provides an additional 15-20% LDL-C reduction through complementary cholesterol absorption inhibition, as reported by the American College of Cardiology 5

Cardiovascular benefit is linearly related to LDL reduction without evidence of a lower threshold, supporting the "lower is better for longer" principle, according to the American College of Cardiology 2, 4
High-intensity statin therapy consistently reduces ASCVD events more than moderate-intensity therapy in patients <75 years of age, as stated by the American College of Cardiology 3
Once on maximally tolerated high-intensity statin therapy, further dose escalation is not the evidence-based next step, and adding non-statin therapy is recommended instead, according to the American Heart Association and the American College of Cardiology 1, 4

The American College of Cardiology recommends confirming the patient is on maximally tolerated high-intensity statin therapy, assessing adherence to medications and lifestyle modifications, and considering adding non-statin therapy if the patient has clinical ASCVD at very high risk and LDL-C ≥55 mg/dL 4
If the patient has clinical ASCVD and LDL-C ≥70 mg/dL, adding ezetimibe is recommended, according to the American College of Cardiology 1, 4

High-dose statin therapy has higher rates of persistent transaminase elevations but rates of myopathy and rhabdomyolysis similar to lower doses, as reported by the American College of Cardiology 1

The American College of Cardiology recommends assessing lipid response 4-12 weeks after adding ezetimibe, then every 3-12 months, and continuing to monitor adherence to lifestyle modifications and medications 4
Apolipoprotein B testing provides superior assessment of residual cardiovascular risk in statin-treated patients compared to LDL-C alone, particularly in those with elevated triglycerides or low HDL-C, as stated by the American College of Cardiology 4